Author: Editor

This discussion between the chairs of the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes” provides a summary of the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages from the Congress. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Alessandro M. Vannucchi argues that early-stage myelofibrosis should be treated. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Paola Guglielmelli discusses the clinical benefit of JAK2 inhibitors in patients with myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Franscisco Cervantes discusses emerging JAK2 inhibitor combination treatment strategies for patients with myelofibrosis. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Mario Cazzola argues that early-stage myelofibrosis should be not treated but should be observed. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

Metastatic Colorectal Cancer” symposium, Eric Van Cutsem discusses the emerging treatment options for metastatic colorectal cancer patients in the late-line setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.

In this presentation from the “Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer” symposium, Dr. Howard S. Hochster discusses the management of adverse events associated with third-line treatments for metastatic colorectal cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.

This discussion presents a discussion between world-renowned thought leaders Axel Grothey, Howard Hochster, and Eric Van Cutsem, who elucidate the effective implementation of new late-line CRC treatments in the clinical setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7199 © 2016 Imedex, LLC.

In this webcast, Dr. David P. Steensma discusses the most pertinent information presented on leukemia and myeloid disorders during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this webcast, Dr. John P. Leonard discusses the most pertinent information presented on lymphoma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this webcast, Dr. Robert Z. Orlowski discusses the most pertinent information presented on multiple myeloma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

Advancements in breast cancer care continue to rapidly evolve and the San Antonio Breast Cancer Symposium (SABCS) is the premier annual forum for exchange of new scientific and clinical information. However, not all healthcare professionals have the opportunity to attend this meeting and even those that do attend often can benefit from taking a deeper dive into the relevance of the data in a smaller venue in which more intimate faculty and peer interactions can take place. This is the role of the annual Best of San Antonio – Breast Cancer: Bench to Bedside meetingto help practicing clinicians interpret the…

Polycythemia vera (PV) is characterized by erythrocytosis, thrombocytosis, and/or leukocytosis with a broad-range of disease-related symptoms that impact the overall health and everyday quality of life of patients. The identification of the high frequency JAK2V617F mutation in patients with PV defines a molecular target for therapeutic intervention. This interactive case-based activity, is designed to complement, accelerate, and reinforce application of knowledge and skills amongst healthcare professionals interested in optimal management strategies for patients with PV. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7194 © 2016 Imedex, LLC.

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen receptor-positive (ER+) metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for this use. This activity discusses the ongoing and planned clinical trials for abemaciclib and ribociclib in ER+ metastatic breast cancer, as well as the future implications for this class of agents in this patient population. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7171 © 2016 Imedex, LLC.

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen ER+ metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for breast cancer. This activity discusses clinical data on the efficacy and safety of the FDA-approved CDK 4/6 inhibitor, palbociclib, in combination with letrozole in ER+ metastatic breast cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7170 © 2016 Imedex, LLC.

The cyclin-dependent kinase (CDK) pathway is critical to cell cycle entry. In many tumor types, including breast cancer, there is dysregulation of this pathway. This activity describes the rationale and mechanism for inhibiting this dysregulated pathway in estrogen receptor-positive (ER+) metastatic breast cancer using selective CDK 4/6 inhibitors. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7169 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Paul Baas discusses updates in the systemic treatment of pleural mesothelioma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Elisabeth Quoix discusses the optimatl treatment of elderly patients with non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Maurice Perol discusses the targeting of angiogenesis for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses the maintenance paradigm for the treatment of non-squamous non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses the first- and second-generation ALK inhibitors for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Rafal Dziadziuszko discusses strategies for overcoming KRAS mutations. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses extreme rare mutations in lung cancer (ROS1, TRK, HER2) and the treatment opportunities available for them. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Nicholas Girard discusses the mechanisms of resistance to EGFR TKIs and new treatment strategies for combating this resistance. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Guilio Rossi discusses the an algorithm for molecular testing of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Gosney discusses the inherent challenges faced by the pathologist in the era of personalized medicine. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses response criteria and kinetics with the use of immunocheckpoint inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses how biomarkers predict the clinical activity of immunocheckpoints. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. David Waller argues that surgery is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Umberto Ricardi argues that steretactic body radiation therapy (SBRT) is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Vansteenkiste discusses the current status of adjuvant thereapy for the treatment of non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Richard Booton discusses the use of endobronchial and other techniquces to opmize the diagnosis and treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses new proposals for a new TNM classification for lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Klaus Irion discusses the use of diagnotics for the staging of lung cancer including the use of functional imaging and volumetric assessment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. John P. Leonard argues that watch and wait may still be utilized in cases of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michael E. Williams argues that “watch and wait” should not be utilized in the treatment of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Andrew M. Evens discusses the latest in the initial management of Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Morton Coleman argues that one should not utilize surveillance imagine for diffuse large b-cell lymphoma (DLBCL) patients in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michell R. Smith argues that we should utilze surveillance imaging for diffuce large b-cell lymphoma (DLBCL) patients who are in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Tracy Batchelor discusses the latest updates in primary CNS lymphoma management. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jonathan Friedberg argues that young paitnts with mantle cell lymphoma (MCL) should not be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Brad S. Kahl argues that young patients with mantle cell lymphoma (MCL) should be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Anas Younas discusses immune checkpoint inhibitors in lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard I. Fisher argues that R-CHOP should be utilized to treat patients with ABC-type diffuce large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Pierluigi Porcu argues that allogeneic stem cell transplant is the best approach for relapsed T cell lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Rafael Bejar discusses the promises and pitfalls in using molecular testing in the diagnosis of myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Selina M. Luger argues that hypomethylating agents should be used with caution in lower-risk patients with myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the management of chronic myelomonocytic leukemia (CMML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben A. Mesa discusses combination therapy with JAK2 inhibitors in the treatment of myeloproliferative neoplasms (MPN). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Sarah Nikiforow discusses the diagnosis and management of hemophagocytic lymphohistiocytosis (HLH). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Kenneth A. Bauer discusses the reversal of newer anticoagulants. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the diagnosis and management of atypical chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Racdich discusses practical advices for the molecular monitoring of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Radich discusses at what point tyrosine kinase inhibitors can be stopped in the treatment of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul Barr argues that the optimal treatment for chronic lymphocytic leukemia (CLL) patients with a 17p deletion is the use of a novel agent. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jacqueline Barrientos argues that ibrutinib is the optimal treatment for chronic lymphocytic leukemia (CLL) patiens with a 17p deletion. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Timothy Call discusses the clinical considerations for the use of oral targeted therapies in chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard R. Furman argues that CR and MRD negativity is no longer required for treatment of CLL in the era of novel agents. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that the best multiple myeloma salvage therapy is KRD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the best multiple myeloma salvage therapy is novel therapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that upfront transplant should no longer be considered a standard of care in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky argues that high risk myeloma should not be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that high risk myeloma should be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the standard induction regimen for myeloma is RVD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky discusses the use of monoclonal antibodies for the treatment of multiple myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses novel approaches to trial design in the era of molecular subtyping. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Karen T. Brown argues that ablation is the optimal treatment of localized hepatocellular carcinoma (HCC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that the optimal treatment of localized hepatocellular carcinoma (HCC) is either resection or transplant. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that chemotherapy alone is the preferred treatment for borderline, resectable pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt argues that epirubicin and other anthracyclines still have a role to play in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. David H. Ilson argues that epirubicin and other anthracyclines no longer have a place in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that the optimal pre-operative therapy for esophagus and GE junction cancers is chemotherapy alone. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses the molecular subtyping/profiling of upper-GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016” Dr. James C. Yao argues that bevacizumab cannot treat pancreatic neuroendocrine tumors (pNET). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Diane Reidy-Lagunes argues that everolimus does not have a role in the treatment of carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. James C. Yao argues that everolimus has a role in carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Mark Andrew Dickson discusses the management of GIST tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael J. Hall discusses genetics in gastrointestinal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Luis A. Diaz discusses the use of liquid biopsies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses novel therapies for gastrointestinal malignancies beyond immunotherapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that biomarkers beyond MSI cannot direct immunotherapy in gastrointestinal malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt discusses inflammation in colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that TAS-102 followed by regorafenib is the preferred salvage therapy for metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that the preferred salvage therapy for metastatic colorectal cancer (mCRC) is regorafenib followed by TAS-102. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC) should be treated with a chemo doublet with EGFR inhibitor. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is not ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that there is no optimal first-line therapy sequence in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that there is an optimal sequence for first-line therapy in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that biomarkers do not have a role in the adjuvant setting for colorectal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses the use of biomarkers for colon cancer treatment selection. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Charles B. Simone examines novel forms of radation delivery, and whether technology can trump biology in the treatment of disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass arguest that a trimodality approach is preferred for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski proposes that a bimodality approarch is preferential for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski discusses whether or not the choice of systemic agents or their sequencing makes a different in combined modality therapy for locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass discusses the mangement of the mediastinum and other surgical issues. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentatino, Dr. Gerard A. Silvestri outlines his perspective on the updated TNM classifications for malignant tumors, and expounds upon whether there is a role for histology of markers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology” Dr. Laura Jean Bierut examines current strategies for curtailing smoking addiction. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Benjamin Levy queries whether liquid biopsy will replace conventional tissue-based sampling. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. William K. Evans discusses the current cost and efficacy of managing non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sven de Vos disuccese new agents for use in the treatment of recurrent follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg argues against the use of maintenance rituximab for the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Gilles Salles argues that maintenance rituxumab should be used in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Thomas E. Witzig discusses how he sequence therapy in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jia Ruan examines the best approach to the initial therapy of peripheral t-cell lymphoma (PTCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presenation, Dr. Kami Maddocks discusses who should get what for upfront therapy of mantle cell lymphoma (MCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Adam M. Petrich discusses the best approach to treat double hit/double protein expression diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John P. Leonard discusses the hurdles to using cell of origin in the classification and treatment of diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Laurie H. Sehn discusses the best approach to limited stage diffuse large b-cell lymphoma (DLBCL), and whether that includes radiation. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Randy Gascoyne discusses the future of lymphoma pathology in the era of tumor profliing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg discusses the highlights from the 2015 International Conference on Malignant Lymphoma, held in Lugano Switzerland. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete responses (CRs) in patients with chronic lymphocytic leukemia (CLL) following long-term treatment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve M. Ansell discusses the use of immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien argues that there is no value to the use of brentuximab vedotin as consolidation therapy following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies” Dr. Robert W. Chen argues that there is value to using brentuximab vedotin as consolidation therapy shorlty following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jeremy Abramson argues that chemotherapy-based regiments are the preferred second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Allison Moskowitz argues that single-agent brentuximab is the best second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Giorgio Inghirami discusses whether or not we can use patient-derived xenografts to assess new lymphoma therapies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Irene M. Ghobrial discusses why Waldenstrom’s and myeloma change from monoclonal gammopathy of undetermine significane (MGUS) to active disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Esteban Braggio discusses how useful genomics is in the clinical practice, with regard to the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien disccusses patient selection criterion for allogeneic transplant as treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John Allan discusses the risks, predictors, and treatment of Richter’s Syndrome. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jennifer R. Brown discusses whether the incidence of familial chronic lymphocytic leukemia (CLL) is increasing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman elucidates the different between the various techniques of using CAR-T cells for the treatment of chronic lymphocytic leukemia (CLL) A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Mitchell R. Smith discusses when and how to use FCR and BR in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve Coutre discusses tyrosine-kinase inhibitors (TKIs), apoptotic enhancers, and other small molecules in the pipeline for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman discusses risk assessment in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kanti Rai discuses the most recently approved tyrosine-kinase inhibitors (TKIs) for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Neil Kay discusses the targeted inhibition of signal molecules as a novel therapy for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kenneth C. Anderson discusses new paradigms and therapies for the treatment of relapsed/refracory myeloma. He discussesthe use fo small molecules and monoclonal antibodies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Guentehr Koehne examines whether there is a role for allotransplant in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sundar Jagannath argues against maintenance therapy in the myeloma setting. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo argues in favor of the use of immunomodulatory drugs (IMiDs) for the maintenance of myeloma patients. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson argues that myeloma patients should be maintained with proteasome inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Tomer Mark argues that it is not necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transplant is therefore unnecessary. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Ajai Chari argues that it is necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transpant facilitates this. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo discusses the best treatment options for transplant-ineligible myeloma patients, and whether those comprise two, three, or four drug regimens. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. David Roodman discusses the advances in both biology and the treatment of myeloma bone disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this abstract presentation, Dr. Paul G. Richardson discusses the results of a mutlicenter Phase 2 trial on the use of ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple meyloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Renier J. Brentjens discusses the latest information on CARS and “armored” CARS as an immunological t-cell treatment of cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jatin J. Shah discusses whether high-risk myeloma should be treated differently and how one should do so. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. C. Ola Landgren examines whether minimum residual disease (MRD) is a necessary clinical tool of evaluation in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson discusses B-cell maturation antigen: a new biomarker for B-cell malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP

Carlos Fernandez de Larrea, MD, PhD from the Hospital Clínic de Barcelona, Barcelona, Spain gives an overview of his talk on response assessment in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Dr de Larrea, the response assessment in MM is crucial. It is important to establish whether a patient has achieved complete remission (CR) and to identify patients who are relapsing or progressing after different lines of treatment. Dr de Larrea further discusses the various techniques used to assess response, such as electrophoresis in serum and urine…

Do I need head and neck specialists for my cancer? Patient Power Founder and Host, Andrew Schorr, discusses this question with Head and Neck Oncologist Dr. Faye Johnson at MD Anderson Cancer Center. Although this question may seem obvious, Dr. Johnson stresses the importance of building a team that are head and neck oncology experts for the best possible rehabilitation and support. This team should include oncology, radiology, surgery, pathology, audiologist and/or speech therapy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

What are the targeted and less toxic treatments for head and neck cancers? Patient Power Founder and Host, Andrew Schorr, interviews Head and Neck Oncologist, Dr. Faye Johnson of The University of Texas MD Anderson Cancer Center in Houston. Dr. Johnson discusses four promising areas of targeted research in head and neck cancers, including immunotherapy and HPV. Dr. Johnson stresses that targeted therapies are best found in clinical trials and shares options on how patients can get connected. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on…

What exactly is MRD? Who should be tested? From the Myeloma 2016 meeting in Boston, Dr. Ola Landgren from Memorial Sloan Kettering Cancer Center explains MRD and what patients should be tested. He goes on to discuss how MRD and other diagnostic tests are being used by doctors in myeloma care, as well as updated guidelines for testing provided by the International Myeloma Working Group (IWMG). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How much of a difference in counts can you expect to see if you have blood drawn and processed at different labs? In this Ask the Expert segment, MPN expert Dr. Naveen Pemmaraju answers this question from viewer, Cindy. Dr. Pemmaraju discusses the variation in labs and offers tips to track your results, following trends versus the results of a single test. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Is stem cell transplant a viable treatment option? How long should maintenance therapy last? From the Myeloma 2016 meeting in Boston, myeloma expert Dr. Thomas Martin from UCSF Medical Center answered these questions and more related to myeloma treatment. He goes on to discuss new and upcoming myeloma treatments as well as the important role that research plays. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power Founder and Host, Andrew Schorr, discusses cancer screening with MD Anderson Cancer Centers Head and Neck Surgeon and Specialist, Dr. Erich Sturgis. Dr. Sturgis details the benefits of screening, particularly with the HPV vaccination. Screening allows specialists to identify cancer early enough in the process to increase the patients chance of successful treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How do I manage my cancer pain? Patient Power Founder and Host, Andrew Schorr, interviews MD Anderson Cancer Center’s pain management specialist, Dr. David Hui. Dr. Hui has devoted his career to helping cancer patients find relief from their pain. Listen as he describes various types of pain and explains how to best manage your care and seek relief. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2016 World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland, Paul Richardson, MD, from the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA gives an overview of his talk on the latest advances in the clinical management of relapsed/refractory multiple myeloma (MM). He discusses several drugs that have been recently approved by the FDA in the US, namely pomalidomide, carfilzomib, the HDAC inhibitor panobinostat, elotuzumab, daratumumab, and ixazomib, which is the first oral proteasome inhibitor. According to Dr Richardson, these new drugs have had a dramatic effect on clinical management due to their novel…

At the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland. Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of a session on what the most appropriate approach to treating patients with relapsed myeloma. One of the key messages is the importance of using multiple drugs for treating multiple clones of the disease, according to Dr Stewart. He further discusses the combination of lenalidomide and dexamethasone as a backbone of carfilzomib, ixazomib and elotuzumab. According to Dr Stewart, randomized trials show that the combination…

What causes lung cancer? Can it be passed on genetically? Lung cancer experts Dr. George Simon of MD Anderson Cancer Center and Dr. Rebecca Heist of Harvard Medical Center discuss various common causes of lung cancer, including chemicals, pesticides and radon exposure. Dr. Simon concludes with screening options, including a new alternative to low-dose CAT scans. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

In this Ask the Expert segment, Patient Power community member, Peggy, wrote, How strong of a connection is there between long-term use of Jakafi and non-melanoma skin cancer? Should a patient quit taking medication? MPN expert Dr. Naveen Pemmarju of MD Anderson Cancer Center responds with a discussion of a journal article and goes on to stress the importance of vigilance and monitoring.

As part of Patient Powers coverage of Myeloma 2016, several renowned multiple myeloma experts joined together to discuss what they learned at the meeting. Drs. Ken Anderson, Keith Stewart, Noopur Raje and Sagar Lonial, discuss how the Myeloma 2016 meeting fosters collaboration among myeloma researchers, from all over the world. The experts discuss new discoveries, genetics, combination therapies, as well as how technological changes are allowing increasing the pace of advances in the field. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Anna Schuh, MD, PhD, from the University of Oxford, UK, gives an overview of her talk on the advances in the molecular stratification of chronic lymphocytic leukemia (CLL). The focus of the talk was to make sense of the biological and clinical heterogeneity of CLL patients. The fludarabine, cyclophosphamide and rituximab (FCR) therapy is still the standard of care frontline treatment and while data shows that many patients respond very well or have even shown to be cured, around 25% of patients will relapse within the first two years of having received chemoimmunotherapy according to Dr Schuh. Molecular markers may…

Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY gives an overview of the case studies on chronic lymphocytic leukemia (CLL) he presented at the 36th World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland. In the first case study, he discusses the use and side effect profiles of ibrutinib as well as idelalisib and rituximab. Dr Zelenetz also addresses the management of the side effects in his first case study. In the second case discussed, Dr Zelenetz discusses how the response to an alternative kinase inhibitor after progession is not very favorable.…

In this Ask the Expert video segment, multiple myeloma expert Dr. Jatin Shah of MD Anderson Cancer Center responds to a question about the reason why patients on multiple myeloma maintenance therapy are are advised to avoid antioxidants, particularly on medication day. Listen as Dr. Shah explains why high doses of vitamin C and green tea, as well as potential other antioxidants, are not recommended for patients on certain maintenance therapies. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

With all of the advances in cancer research, where does the field of prostate cancer stand? Andrew Schorr, Patient Power Founder, speaks with genitourinary clinician and researcher, Dr. Russell Szmulewitz, about the latest prostate cancer updates. Dr. Szmulewitz is very hopeful based on hormone therapies, current medications, and the climate of collaboration among international researchers. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

This was my talk at the University of Minnesota’s Masonic Cancer Center Seminar Series on May 10, 2016. I review translational approaches to cancer research, areas of cancer research that should be reassessed, and novel approaches to strategies that can be used in the lab to address clinically relevant questions in oncology. More information on my laboratory research and clinical work can be found on my UMN website: https://www.dom.umn.edu/divisions/hematology-oncology-and-transplantation/lou-lab

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses current developments in myeloproliferative neoplasms (MPNs) at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) held in Glasgow, Scotland. According to Dr Mesa, it is a very exciting time for MPNs as new JAK inhibitors such as pacritinib and NS-018, anti-fibrosing agents such as PRM-151 as well as telomerase inhibitors such as imetelstat, are being developed.

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses how to manage adult myeloproliferative neoplasm (MPN) patients at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. An understanding of the patients’ risk, molecular features and their symptom burden is key to assessing their treatment options. Dr Mesa further discusses the prevention of vascular events through the use of aspirin and cytoreduction.

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA provides an overview of his talk on individualizing care for myeloproliferative neoplasm (MPN) patients held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. The focus is on understanding the indvidual patient’s disease burden and risk for molecular features and devising a plan for the patient that includes the prevention of vascular events and the avoidance of disease progression. Dr Mesa also discusses some of the key considerations that need to be taken into account for each patient,…

Peter Hillmen, MD, PhD, from St. James’ University Hospital, Leeds, UK gives an overview of the RESONATE-2 trial (NCT01722487), a randomized Phase III trial of ibtrutinib in chronic lymphocytic leukemia (CLL). The trial compared inbrutinib to chlorambucil and showed a significant improvement in progression-free survival (PFS), which was the primary endpoint, and further an overall survival (OS) advantage for patients on the ibrutinib arm. Overall, ibrutinib was well tolerated according to Prof Hillmen. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK discusses the potential benefit of a higher dose of daunorubicin for a sub-group of acute myeloid leukemia (AML) patients with the FLT3-ITD mutation. This study was conducted as part of the AML17 trial and the abstract was presented at the 2016 World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland. Patients were randomized to receive two different doses of daunorubicin at induction therapy. Prof Russell discusses the initial report, which showed that there was no advantage to using the higher dose of daunorubicin. However, further…

Gilles Salles, MD, PhD, from South Lyon Hospital Complex, Lyon, France discusses the management of patients with follicular lymphoma in the first-line and relapsed setting. Prof Salles outlines the different treatment approaches for patients with limited stage and extended stage disease. For example, patients with limited stage disease may receive radiation therapy and for patients with a high-tumor burden, the standard of care has been chemotherapy plus an anti-CD20 such as rituximab. Prof Salles further discusses the option of a chemotherapy-free approach and the various options in the relapsed setting. Recorded at the 2016 Annual Meeting of the British Society…

Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK talks about new and emerging drug targets in acute myeloid leukemia (AML). Prof Russell discusses the FLT3 mutation, which is one of the most established targets and has been a focus of research for several years, acute promyelocytic leukemia (APL), as well as the IDH1, IDH2 and NPM1 mutations. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

Gilles Salles, MD, PhD, from South Lyon Hospital Complex, Lyon, France provides an overview of his presentation on ‘chemo-free’ in follicular lymphoma held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), in Glasgow, Scotland. Prof Salles outlines the limitations of chemotherapy and the reasons why he supports a ‘chemo-free’ approach. He argues that chemotherapy is not curative and that agents that can modify the microenvironment, may be successful at managing the disease. For example, monoclonal antibodies such as anti-CD20, either alone or when combined with chemotherapy, can improve the survival…

Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the tolerability of monoclonal antibodies. According to Prof Martin, monoclonal antibodies are well tolerated, however, at the first infusion there can be infusion-related reactions. Recorded at the Myeloma 2016 meeting held in Boston, MA.

Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the use of monoclonal antibody therapy in multiple myeloma (MM). Daratumumab and elotuzumab are already approved and according to Prof Martin, the next monoclonal antibody to be approved will be isatuximab. Isatuximab like daratumumab, targets CD38 and responses to the drug in pre-clinical work and clinical trials have been good. In the initial Phase I trial in relapsed/refractory myeloma (NCT01749969), the response rate to isatuximab was over 30% and in combination with lenalidomide and dexamethasone, the response rate was in the 60% range. Prof…

Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the use and side effects of venetoclax for multiple myeloma (MM) in clinical practice. Venetoclax is very potent in chronic lymphocytic leukemia (CLL) and Prof Boise describes how patients treated with the drug had to stay in hospital due the associated toxicity. Multiple myeloma patients are also initially treated in hospital during the first cycle but are then able to go home. According to Prof Boise, venetoclax is fairly well tolerated and has also been tested in combination with bortezomib and dexamethasone. Recorded at the Myeloma 2016 meeting held…

Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA discusses the possibility of exploiting the biology of the plasma cell for drug therapy in multiple myeloma (MM). Prof Boise mentions the targeting of the cell surface proteins CD28 and CD86 and translating findings into clinical practice. Recorded at the Myeloma 2016 meeting held in Boston, MA.

Faith Davies, MBBCh, MRCP, MD, FRCPath from UAMS Myeloma Institute, Arkansas, AZ discusses the importance of the microenvironemt in multiple myeloma at the Myeloma 2016 meeting held in Boston, MA. In light of findings that have established the importance of the microenvironment, Prof Davies further talks about the possibility of new drug combinations, such as combining HDAC inhibitors with immune check-point inhibitors.

Antonio Palumbo, MD, from the University of Turin, Turin, Italy, provides an overview of his talk on ‘Perspectives on future paths to cure’ held at the Myeloma 2016 meeting in Boston, MA. According to Dr Palumobo, the key message is that the survival of patients with multiple myeloma (MM) has improved over the last 15 years. Dr Palumbo further discusses the prospect of being able to cure a proportion of patients and further highlights that currently, the use of a dose intense treatment at diagnosis is important as with this approach, remission durations of around six or even ten years…

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, discusses multiple immune checkpoint molecules, including PD-L2, gamma interferon, IDO, TIM3 LAG-3 B7H3, that may have clinical relevance for the treatment of patients with lung cancer.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses immunotherapy as a key theme of the conference, including current data and future concepts, efficacy in untreated patients, efficacy in combination approaches, and biomarker-based treatment selection.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the detection of anaplastic lymphoma kinase gene (ALK) rearrangements and fusions in patients with non-small cell lung cancer.

Pages Image Alignment

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Enriqueta Felip, MD, PhD, from Vall dHebron Institute of Oncology, Barcelona, Spain, provides an overview of therapeutic approaches based on an increasing molecular level understanding of tumors to overcome acquired resistance in patients with non-small cell lung cancer.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses results from ASCEND-1 and ASCEND-2, two non-randomized phase 1/2 multicenter, open-label, single-arm trials evaluating the efficacy of ceritinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, in patients with pretreated, ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, explains that there has been significant progress in the development of immunotherapy for lung cancer and clinical trial design in immunotherapy should be tailored to the patterns of response and outcomes observed for this approach.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses LUX-Lung 7, a phase 2b, global, randomized, open-label trial of afatinib compared with gefitinib as first-line treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial evaluating the combination of chemotherapy and gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), as first-line treatment for patients with advanced lung adenocarcinoma and activating EGFR mutations.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Enriqueta Felip, MD, PhD, from Vall dHebron Institute of Oncology, Barcelona, Spain, discusses results from a retrospective study showing the continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses biomarkers, including biomarkers of DNA repair and related pathways, for predicting treatment response to chemotherapy and radiotherapy in patients with non-small cell lung cancer (NSCLC).

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses the characterization of tumor-infiltrating lymphocytes in resectable early stage non-small cell lung cancer (NSCLC) and the application of this understanding for the development of immunotherapy in early stage disease.

Faith Davies, MBBCh, MRCP, MD, FRCPath from UAMS Myeloma Institute, Arkansas, AZ gives an update on the use of trametinib, which is a MEK inhibitor, in multiple myeloma (MM). The response rate was 20% when given as a single agent and around 50% when given in combination with other drugs in patient with a RAS mutation. According to Prof Davies, the question is why the response is not 100% and her group has looked at, for example, clonal heterogeneity and the downstream expression of RAS in attempt to find an answer to this question. There may also be other groups…

Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses the various features of multiple myeloma (MM) that make assessing response in myeloma challenging. According to Dr Paiva, myeloma is a heterogeneous disease and the correlation between depth of response and clinical benefit, is not as evident in MM as compared to other malignancies. Further, while minimal residual disease (MRD) levels help assess the prognosis for patients with other malignancies, patients with MRD in MM generally do poorly. In recent years, however, there have been improvements in techniques such as PET-CT, which are helping to improve response assessment. Dr…

Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, gives an overview of matched unrelated donor (MUD) transplantation for acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). MUD transplantation means that the transplant is from an unrelated donor. For AML, a transplant is the only curative treatment to date according to Prof Nagler. The issues with transplantation is graft-versus-host disease (GvHD) and finding an eligible donor. Unrelated donors are volunteers and due to advances in the field of transplantation, outcomes in patients who have received a transplant from an unrelated donor compared to patients who have received a…

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK gives an overview of the field of CAR T-cells. With both allogeneic and autologous CAR T-cells under development questions are being raised about their recommended uses and cost of development.

Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of the ‘off the shelf’ use of virus-specific T cell therapy. At the moment, the therapy targets 5 viruses but the aim is to include more viruses over time. Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

Niels van de Donk, MD, PhD, from the University Medical Center, Amsterdam, Netherlands discusses the use and mechanism of action of daratumumab. Daratumumab is an anti-CD38 targeting antibody and has shown high activity in end stage patients with multiple myeloma (MM). Dr van de Donk further explains that it has been shown to eliminate CD38 positive immune suppressor cells. This means that a sub-population of regulatory T-cells, which are CD38 positive, are killed during daratumumab therapy. According to Dr van de Donk, CD38 high regulatory T-cells are very immunosuppressive and the elimination of these kinds of cells by daratumumab, is…

Marta Chesi, PhD, from the Mayo Clinic, Scottsdale, AZ discusses LCL-1 for the treatment of multiple myeloma (MM). LCL-1 has an affinity to the cellular inhibitors of apoptosis, cIAP1 and cIAP2. cIAP1 is frequently deleted in myeloma patients and as Dr Chesi explains, when she first treated transgenic mice with LCL161, she expected that it would promote the growth of myeloma as it activates NF-kappa B. However, she observed the opposite, i.e. the tumor burden was reduced in the mice. She further explains that NF-kappa B was activated in the tumor cells as well as the host, which gave the…

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial of the efficacy and safety of BI 1482694 (HM61713), a third-generation epidermal growth factor receptor (EGFR) mutant-specific tyrosine kinase inhibitor (TKI), for the treatment of patients with T790M-positive non-small cell lung cancer (NSCLC).

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Keith Kerr, BSc, MB ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, United Kingdom, discusses biomarker-based selection of therapy and the progress in understanding clinically relevant biomarkers in patients with lung cancer.

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, John Murray, a Nurse Clinician at the Christie NHS Foundation Trust, Manchester, UK, talks about a standalone nurses day meeting focused on a bone marrow transplant consent. This session gives a better understanding of how patients decide on agreeing to undergo the procedure, from both psychologist’s and patient’s point of view. With limited time to ask questions during clinic hours this information gives a valuable insight into patient’s motivations.

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, Jane Apperley, MD from Imperial College London, London, UK discusses developments leading to gene therapies for the management of graft-versus-host-disease (GvHD) and CAR T-cells designed specifically for Acute Myeloid Leukemia (AML) and Myeloma.

Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses the success of targeted drugs such inotuzumab ozogamicin in adult acute lymphoblastic leukemia (ALL) and suggests that physicians should rapidly adpot these new drugs for clinical use. Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses the history of veno-occlusive disease (VOD) and defibrotide, which was developed to improve survival rates of patients affected by this devastating condition.

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, Jane Apperley, MD from Imperial College London, London, UK gives an overview of EBMT 2016 presentations focused on graft-versus-host-disease (GvHD) and metabolic syndrome.

Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses how inotuzumab ozogamicin is now used as a frontline therapy in adult acute lymphoblastic leukemia (ALL). According to Prof Martinelli, this means that patients can be treated with more intensive chemotherapy later on or receive a bone marrow transplantation to consolidate the therapy. The future will be without chemotherapy according to Prof Martinelli. Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses improvements in supportive care and diagnostics for acute myeloid leukemia (AML). Further work is required to improve outcomes of high-risk patients.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Zoran Gatalica, MD, DSc, from Caris Life Sciences, Phoenix, AZ, discusses a study evaluating the differences in expression of multiple biomarkers of targeted biological therapies, immune checkpoint inhibitors and chemotherapeutic agents between primary and metastatic tumors in patients with non-small cell lung cancer (NSCLC).

The Myeloma 2016 meeting, was held in Boston, MA, between 2224 April. Keith Stewart MB, ChB from the Mayo Clinic, discusses the day 1 highlights with Sagar Lonial, MD of the Winship Cancer Institute, Kenneth Anderson, MD of the Dana-Farber Cancer Institute, and Leif Bergsagel, MD of the Mayo Clinic. Here the experts discuss the possible targets of cellular immunotherapy, using CAR T-cells and BiTE as the vehicles; minimum residual disease (MRD), the new next-generation flow cytometry techniques available and its use in the drug approval process; among other treatment-related topics.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, explains the development of antibodies targeting the programmed death ligand 1 (PD-L1) and its receptor, programmed death 1 (PD-1) for the treatment of patients with non-small cell lung cancer (NSCLC), including clinical trials evaluating the integration of PD-1/PD-L1blocking antibodies with existing standard-of-care approaches.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the identification of actionable mutations in tumors for the development of personalized medicine for patients with lung cancer, including for the identification of patients with acquired resistance associated with T790M mutation.

Michael P Kosty, MD, FACP, FASCO Medical Director, Scripps Green Cancer Center gives an update on Immunotherapy of Lung Cancer

Dr. Richard Essner, M.D., F.A.C.S. Cedar Sinai Cancer Center Surgical Director, Melanoma Program discusses the New Role of Surgery in the Treatment of Melanoma

Dr.Michael Alvarado, MD and Dr. Rick Baehner, MD present case studies and a presentation on Genomic Update in Hormone Receptor Positive Breast Cancer

Dr. Daniel S. Oh, MD Assistant Professor of Surgery Division of Thoracic Surgery Keck Medical Center of USC discusses how we can improve early stage lung cancer outcomes.

Dr. Jorge J. Nieva, MD Associate Professor of Clinical Medicine University of Southern California discusses a study conducted by Memorial Sloan Cancer Center in where the objectives were Validate the CCP gene signature (CCP score) and a Prognostic Score that identify stage I non-small cell lung cancer patients with a higher risk of cancer-related death after surgical resection

Dr. Samuel J. Klempner, MD Director of Precision Medicine The Angeles Clinic and Research Institute discusses how Diagnostic Dilemmas and Early Barriers Changing the Cancer Classification, Molecular Epidemiology, Response and Resistance Tumor Mutational Load and Immunotherapy, Liquid Biopsies

Dr. Omid Hamid MD of the Chief, Translational Research & Immuno-Oncology  Director, Cutaneous Malignancies, The Angeles Clinic and Research Institute discusses how Immuno-Oncology will affect not only melanoma but many other disease states within oncology.

Sybil R. Green, JD, RPh, MHA ACC, LOS, MOS from ASCO discusses how the updated government program called MACRA will affect payments to oncologist in the very near future.

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the Champalimaud Clinical Center, Lisbon, Portugal, discusses the role of personal development and advocacy by healthcare professionals to address inequalities and unmet needs in patients with breast cancer around the world. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Jan-Willem Coebergh, MD, PhD, from Erasmus MC, Rotterdam, the Netherlands, summarises future directions in the epidemiology of breast cancer, including the efforts to systematically assess patient experiences and quality of care. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the Champalimaud Clinical Center, Lisbon, Portugal, discusses the collaboration between the European School of Oncology and Pfizer in the development of the Global Status of MBC: A Decade Report, an analysis of the global metastatic breast cancer landscape from 20052015. Despite showing areas of improvement, unmet needs were identified in patients with metastatic breast cancer, including the need for improved disease awareness, research and patient support. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Jeremy Thomas, MD, from Western General Hospital, Edinburgh, United Kingdom, discusses the results of a central pathology review, including tumour type, histological grade and lymphatic invasion, of the SUPREMO trial, a randomised, global phase 3 clinical trial evaluating radiotherapy after mastectomy for patients with intermediate-risk breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Andrew Evans, MRCP, FRCR, from the University of Dundee, Dundee, United Kingdom, explains the opportunities and challenges associated with the use of imaging biomarkers to predict disease behaviour in patients with breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses ASSESS, a trial of the utility of circulating-free tumor DNA in the plasma for the detection of epidermal growth factor receptor (EGFR) mutation status in patients with advanced non-small cell lung cancer.

Dr. John Gribben, University of London, and Dr. Constantine Tam, Peter MacCallum Cancer Centre, join Patient Power Founder, Andrew Schorr, to discuss the current frontline treatment advances for CLL. Learn more about the results of the Resonate II trial, including survival advantages and durable control, as well as cumulative toxicity and cost. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

The session was held in collaboration with EONS (European Oncology Nursing Society) and discussed the management of skin reactions due to radiotherapy

This session was held in collaboration with EONS (the European Oncology Nursing Society) and explores treatments options in case of malignant fungating wounds

This session was held in collaboration with EONS (European Oncology Nursing Society) and covers the specific difficulties health care professionals have to face when dealing with Teenagers or Young Adults with cancer.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Enriqueta Felip, MD, PhD, from Vall dHebron Institute of Oncology, Barcelona, Spain, discusses CheckMate 171, a multicenter phase 2 trial of nivolumab, an anti-PD-1 monoclonal antibody, in patients with stage IIIB/IV squamous cell non-small cell lung cancer who have received at least one prior systemic treatment.

Is there a positive correlation between the use of a JAK Inhibitor and stem cell transplant (SCT)? UK viewer, Peter, asks about the recommended use of a JAK inhibitor prior to having a SCT. MPN expert Dr. Naveen Pemmaraju from MD Anderson Cancer Center responds with a discussion of two studies on this subject and the role of SCT for MPN patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Toxicity as a Biomarker Frede Donkosov MD

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK talks about the crucial role that nurses play in the fungal disease management.

At the 2016 Annual Meeting of the Europea n Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Catherine Bollard, MD, from Children’s National Health System, Washington, D.C., provides an overview of the toxicities, including cytokine release syndrome that correlates with both toxicity and efficacy, which can be observed in patients with acute lymphoblastic leukemia (ALL) who are undergoing chimeric antigen receptor (CAR) T-cell therapy.

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses isavuconazole for fungal disease treatment in leukemia patients. Isavuconazole has less toxicity than voriconazole and shows significant activity over mucormycosis. It has an oral and intravenous (IV) formulation which essential in treatments of sick patients.

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, John Gribben, MD, from Barts Cancer Institute, London, UK, discusses how chronic lymphocytic leukemia (CLL) patients could soon benefit from specific treatments based on CLL characterization and their disease biology.

Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, and President of the European Society for Blood and Marrow Transplantation (EBMT), talks about the IFM Spotlight session hosted at the 2016 Annual Meeting of EBMT, held in Valencia, Spain. This non-sponsored session covered the clinical trial IFM/DFCI2009 in multiple myeloma (MM), where the first interim results were presented by Prof. Mohty. Patients received an induction treatment with lenalidomide, bortozomib and dexamethasone (VRD), either followed by transplant and consolidation with VRD and maintenance with lenalidomide; or, no transplant, consolidation with VRD and maintenance with lenalidomide. The primary endpoint was progression-free survival…

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, John Murray, a Nurse Clinician at the Christie NHS Foundation Trust, Manchester, UK, discusses the role of a good nursing care in the veno-occlusive disease (VOD) management. VOD is a rare complication with 80% mortality in severe cases. Recognition of symptoms, such as weight gain or right upper quadrant pain by nurses means that action can be taken and compications reduced.

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Catherine Bollard, MD, from Children’s National Health System, Washington, D.C., explains some of challenges associated with multicenter trials of genetically modified T-cell immunotherapy, including the standardisation process of managing toxicities observed in patients following T-cell infusion.

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses antifungal prophylaxis in leukemia patients. With therapies focused mainly on disease relapse it is important to remember that morbidity and mortality of fungal disease is significant.

Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of virus-specific T cells from how they were first developed to the advances that have been made to date. Dr Leen describes how virus-specific T cell were first developed to target Epstein-Barr virus (EBV) and cytomegalovirus (CMV), which are problematic in immunocompromised individuals. She further explains why virus-specific T cells are important for patients who are immunocompromised and how the spectrum of viruses that can be targeted, has been expanded to include adenoviruses, the BK virus, and human herpesvirus 6. According to Dr Leen, one of…

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, John Murray, a Nurse Clinician at the Christie NHS Foundation Trust, Manchester, UK, discusses how to manage anxiety and fear in patients undergoing the bone marrow biopsy procedure. A detailed discussion helps patients understand the process and relax, despite uncomfort or pain. In some cases Entonox gas or intravenous midazolam can be used to reduce anxiety levels.

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Gesine Bug, MD from University Hospital Frankfurt, Frankfurt/Main, Germany discusses a clinical trial with 40 high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients treated with panobinostat and donor lymphocyte infusions (DLI). Promising results of the study showing that the combination of the two treatments has a potential to inhibit a disease relapse will be validated further in a randomised clinical trial next year.

Where do we stand in understanding and diagnosing prostate cancer? Patient Power founder, Andrew Schorr, visits with renowned expert Dr. William Catalona, from Robert H. Lurie Comprehensive Cancer Center of Northwestern University, to discuss advances in understanding prostate cancer. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power Founder and host, Andrew Schorr interviews CLL expert Dr. Richard Furman to discuss the evolving CLL treatment landscape, including the introduction of venetoclax (Venclexta) to the CLL armamentarium. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

What new identifying factors are making a difference for lung cancer patients? Patient Power founder Andrew Schorr interviewed lung cancer expert Dr. Rebecca Heist, hematologist/oncologist at Massachusetts General Hospital, asking her opinion on the expanding armamentarium. Dr. Heist discusses multiple dynamics including targeted therapies, inhibitors, newly discovered targets, immunotherapies, and resistance therapies aimed at mutations. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Andrew Schorr asks lung cancer expert Dr. Rebecca Heist of Harvard Medical School to discuss the advances made in brain metastases treatments for lung cancer patients. Listen as Dr. Heist expresses her positive outlook: This is a time of incredible hope in lung cancer. There is so much research and progress being made. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses optimizing the use of tyrosine kinase inhibitors (TKIs) and movement towards personalized approaches for the treatment of patients with oncogene-addicted non-small cell lung cancer, including epidermal growth factor receptor (EGFR)-mutant and anaplastic lymphoma kinase (ALK)-mutant patients.

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, provides an overview of the improvements in the treatment of patients with non-small cell lung cancer (NSCLC) carrying the anaplastic lymphoma kinase (ALK) gene rearrangement, including ALK-targeted therapies with improved bloodbrain barrier penetrance and understanding of resistance mechanisms.